A Randomized, Controlled Phase III Trial to Evaluate the Efficacy of Elortinib vs Gefitinib in Advanced Non-small-cell Lung Cancer With EGFR Exon 19 or 21 Mutations

Chinese Society of Lung Cancer1 site in 1 country256 target enrollmentJuly 2009

ConditionsThoracic Neoplasms

Interventionserlotinib gefitinib

Drugserlotinib gefitinib

Overview

Phase: Phase 3
Intervention: erlotinib
Conditions: Thoracic Neoplasms
Sponsor: Chinese Society of Lung Cancer
Enrollment: 256
Locations: 1
Primary Endpoint: progression-free survival
Status: Completed
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This is a randomized controlled trial to compare efficacy and safety between erlotinib and gefitinib in advanced NSCLC harboring EGFR exon 19 or 21 mutations.Eligible patients were randomized to receive erlotinib or gefitinib in any line settings.The primary endpoint was progression-free survival (PFS).

Detailed Description

Patients with stage IV NSCLC who have EGFR exon 19 or 21 mutations will randomized to received oral erlotinib 150mg or gefitinib 250mg once daily until disease progression or unacceptable toxicity. Method of direct DNA sequencing of tumor tissue is used to analysis EGFR mutation status of exons 18-21. The response will be evaluated by RECIST criteria first month,second month and then repeat every 3 months after the beginning of the treatment weeks.

Registry

clinicaltrials.gov

Start Date

July 2009

End Date

June 2015

Last Updated

9 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Chinese Society of Lung Cancer

Responsible Party

Principal Investigator

Yi-Long Wu

Professor

Chinese Society of Lung Cancer

Eligibility Criteria

Inclusion Criteria

•Histologically or cytologically confirmed stage IIIB (wet) or IV NSCLC.
•Patients with positive EGFR exon19 or exon21 mutation as confirmed by direct sequencing histologically.
•Signing the informed consent form.
•The vital organ functions are tolerant to therapy.
•Have recovered to CTCAE2 grade below from toxicity of previous chemotherapy and radiotherapy
•PS 0-2 scores.
•Functional reserve of bone marrow is adequate, e.g. white blood cell count ≥3.0×109/L, planet count ≥90×109/L, and HB≥80×109/L.
•Serum bilirubin is 2 times less than the upper limit of normal (ULN), ALT and AST are 3 times less than ULN; for liver metastases, ALT and AST need to be 5 times less than ULN; creatinine should be 2 times less than ULN.